Retatrutide Explained: The Triple Agonist Beating Ozempic & Mounjaro
Retatrutide is redefining fat loss. In this episode of Unbreakable Vitality, discover how this triple agonist activates GLP-1, GIP, and glucagon receptors to deliver up to 24% weight loss in just 48 weeks. Learn how it targets visceral fat, insulin resistance, and liver health. This isn’t hype—it’s the next wave of metabolic medicine.
Watch now and subscribe for cutting-edge longevity insights!
https://www.youtube.com/watch?v=s9gq3rY4w